A multi-targeted, barrier-penetrating inhalable nanoplatform for simultaneous immunomodulation and antifibrotic therapy in idiopathic pulmonary fibrosis
Materials Today Bio · 2026-12 · 41 · 103805
DOI: 10.1016/j.mtbio.2026.103805 ↗Kurz gefasst
Fachartikel in der Zeitschrift Materials Today Bio, 2026-12. Verfasst von Yuyao Sun und 9 weiteren Autor:innen. Beteiligte Einrichtung: Department of Pharmacy, The First Affiliated Hospital of Wannan Medical University (Yijishan Hospital of Wannan Medical University), Wuhu, 241001, Ch…. Die Arbeit nennt 63 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Jiangsu Province Natural Science Foundation.
Abstract (Originalsprache)
Idiopathic pulmonary fibrosis (IPF) is a progressive and fatal lung disorder characterized by excessive extracellular matrix (ECM) accumulation, myofibroblast activation, and chronic inflammation. Current pharmacotherapies are hindered by modest anti-fibrotic efficacy and poor drug accumulation within fibrotic lesions. Herein, we developed an inhalable, collagenase-modified liposomal nanoplatform co-encapsulating methylprednisolone and pirfenidone (termed CMPNPs) to address these limitations. The CMPNPs exhibited favorable physicochemical properties and retained collagenase activity under atomization-induced shear forces, enabling efficient penetration through collagen-dense barriers and enhanced lung accumulation. In vitro, CMPNPs suppressed TGF-β1-induced myofibroblast differentiation and migration, and shifted macrophage polarization away from pro-fibrotic and pro-inflammatory phenotypes. In a bleomycin-induced IPF mouse model, inhaled CMPNPs improved survival, reduced collagen deposition and fibrotic lesions, and demonstrated superior lung retention and anti-fibrotic efficacy compared to intravenous administration. Collectively, this multi-targeted, barrier-penetrating strategy overcomes key bottlenecks of current IPF therapies and offers a promising translatable approach for treating progressive pulmonary fibrosis.
Schlagwörter
Stichwörter der Autor:innen
Autor:innen und Institutionen
- Department of Pharmacy, The First Affiliated Hospital of Wannan Medical University (Yijishan Hospital of Wannan Medical University), Wuhu, 241001, China.
- School of Pharmacy, Wannan Medical University, Wuhu, 241002, China.
- Anhui Innovative Center for Drug Basic Research of Metabolic Diseases, Wannan Medical University, Wuhu, 241002, China.
- School of Pharmacy, Anhui Medical University, Hefei, 230032, China.
Förderung
- Jiangsu Province Natural Science Foundation
Zitieren
APA
Sun, Y., Yu, C., Zhang, C., Li, Y., Zhang, W., Li, B., Song, M., Wang, L., Li, B., & Xu, Q. (2026). A multi-targeted, barrier-penetrating inhalable nanoplatform for simultaneous immunomodulation and antifibrotic therapy in idiopathic pulmonary fibrosis. Materials Today Bio, 41, 103805. https://doi.org/10.1016/j.mtbio.2026.103805
Vancouver
Sun Y, Yu C, Zhang C, Li Y, Zhang W, Li B, et al. A multi-targeted, barrier-penetrating inhalable nanoplatform for simultaneous immunomodulation and antifibrotic therapy in idiopathic pulmonary fibrosis. Materials Today Bio. 2026;41:103805. doi:10.1016/j.mtbio.2026.103805
BibTeX
@article{Sun2026,
author = {Sun, Yuyao and Yu, Chenggong and Zhang, Chaochao and Li, Ying and Zhang, Wenqing and Li, Bowei and Song, Mengli and Wang, Lin and Li, Bowen and Xu, Qingwen},
title = {A multi-targeted, barrier-penetrating inhalable nanoplatform for simultaneous immunomodulation and antifibrotic therapy in idiopathic pulmonary fibrosis},
journal = {Materials Today Bio},
year = {2026},
volume = {41},
pages = {103805},
doi = {10.1016/j.mtbio.2026.103805}
}
EUVIMED